What is JBIO's interest income (expense), nonoperating?

JBIO (JBIO) reported interest income (expense), nonoperating of $3.1M in Q1 2026.

How has JBIO's interest income (expense), nonoperating changed year-over-year?

JBIO's interest income (expense), nonoperating increased by 404.4% year-over-year, from $615K to $3.1M.

What is the long-term trend for JBIO's interest income (expense), nonoperating?

Over 4 years (2021 to 2025), JBIO's interest income (expense), nonoperating has grown at a 230.8% compound annual growth rate (CAGR), from $65K to $7.78M.

JBIO JBIO Interest Income (Expense), Nonoperating

Interest Income (Expense), Nonoperating at other companies

Avalo TherapeuticsAVTX

——

Other financials

Income statement

See full

Operating income-$43.4M-85.8%

Net income-$40.4M-5.8%

EPS (diluted)-$0.57+95.3%

Balance sheet

See full

Cash & equivalents$55.1M+24.6%

Total debt$808.0K+159%

Total equity$296.5M+455%

Total assets$319.4M+312%

Cash flow

See full

Operating cash flow-$24.1M-28.4%

CapEx$3.0K—

Free cash flow-$33.7M—

Valuation

See full

Market cap$1.33B+318%

Enterprise value$1.28B—

Returns & leverage

See full

Return on equity-132.5%+120pp

Debt / equity0×—

Current ratio14.3×-17.7×

Where this comes from

Reported directly by JBIO in its filing.

Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNonoperatingNet.

The official record: JBIO’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's interest income (expense), nonoperating.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is JBIO's interest income (expense), nonoperating?: JBIO (JBIO) reported interest income (expense), nonoperating of $3.1M in Q1 2026.
How has JBIO's interest income (expense), nonoperating changed year-over-year?: JBIO's interest income (expense), nonoperating increased by 404.4% year-over-year, from $615K to $3.1M.
What is the long-term trend for JBIO's interest income (expense), nonoperating?: Over 4 years (2021 to 2025), JBIO's interest income (expense), nonoperating has grown at a 230.8% compound annual growth rate (CAGR), from $65K to $7.78M.